Revenue - Additional Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
May 31, 2021 |
Dec. 31, 2020 |
|
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue | $ 224,000 | $ 756,000 | $ 366,000 | $ 16,455,000 | ||||
| Upfront cash payment received | 56,767,000 | 56,767,000 | $ 52,096,000 | $ 81,572,000 | ||||
| Collaboration Agreement with AstraZeneca | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue | 400,000 | 15,000,000 | ||||||
| Upfront cash payment received | $ 40,000,000 | $ 20,000,000 | ||||||
| Milestone payments received | 0 | 10,000,000 | $ 10,000,000 | |||||
| Research Collaboration Income | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue | 224,000 | 756,000 | 366,000 | 16,312,000 | ||||
| Royalty Income | ||||||||
| Disaggregation of Revenue [Line Items] | ||||||||
| Revenue | $ 0 | $ 0 | $ 0 | $ 143,000 | ||||
| X | ||||||||||
- Definition Milestone payments received. No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|